Advanced Search

Cost Effectiveness of Implantable Cardioverter-Defibrillators for Primary Prevention in a Belgian Context

Contents:

Author Info

  • Mattias Neyt

    (Belgian Health Care Knowledge Centre (KCE), Administratief Centrum Kruidtuin, Brussels, Belgium)

  • Nancy Thiry

    (Belgian Health Care Knowledge Centre (KCE), Administratief Centrum Kruidtuin, Brussels, Belgium)

  • Dirk Ramaekers

    (Belgian Health Care Knowledge Centre (KCE), Administratief Centrum Kruidtuin, Brussels, Belgium)

  • Hans Van Brabandt

    (Belgian Health Care Knowledge Centre (KCE), Administratief Centrum Kruidtuin, Brussels, Belgium)

Registered author(s):

    Abstract

    Background: Implantable cardioverter-defibrillator (ICD) therapy was traditionally applied in patients who survived a cardiac arrest or who experienced a symptomatic ventricular tachyarrhythmia. Its use in primary prevention (i.e. in patients who have yet to experience a serious arrhythmic event, but who are considered at high risk for sudden cardiac death) has become more common, and policy makers question whether ICD therapy should be reimbursed in these instances. Objective: To assess the cost effectiveness of primary prevention ICD therapy versus conventional therapy from the perspective of the Belgian health insurance system. Method: A lifetime 1-month cycle Markov model was constructed and populated with clinical and effectiveness data from the SCD-HeFT study and real-world Belgian cost data expressed in year 2005 values. Probabilistic modelling and sensitivity analyses were performed. Results: ICD therapy results in 1.22 life-years gained (LYG) or 1.03 QALYs gained. The lifetime cost-effectiveness and cost-utility ratios were _59_989 (95% CI 35_873, 113_518) per LYG and _71_428 (95% CI 40_225, 134_623) per QALY gained, respectively. A cost-effectiveness ratio <_50_000 per QALY gained was obtained in 15.5% of 1000 simulations. Increasing the service life of the device from 5 to 7 years would improve the cost effectiveness to _57_229 (95% CI 32_568, 106_410) per QALY gained. Conclusions: ICD therapy may not be judged cost effective for the primary prevention of death in patients with a SCD-HeFT profile in the Belgian context using current technology and patient selection. A combination of price reductions and increased service life of the device may alter this conclusion. DOI: 10.2165/0148365-200806010-00006

    Download Info

    If you experience problems downloading a file, check if you have the proper application to view it first. In case of further problems read the IDEAS help page. Note that these files are not on the IDEAS site. Please be patient as the files may be large.
    File URL: http://healtheconomics.adisonline.com/pt/re/ahe/pdfhandler.00148365-200806010-00006.pdf
    Download Restriction: Pay per view
    File URL: http://healtheconomics.adisonline.com/pt/re/ahe/fulltext.00148365-200806010-00006.htm
    Download Restriction: Pay per view

    As the access to this document is restricted, you may want to look for a different version under "Related research" (further below) or search for a different version of it.

    Bibliographic Info

    Article provided by Springer Healthcare | Adis in its journal Applied Health Economics and Health Policy.

    Volume (Year): 6 (2008)
    Issue (Month): 1 ()
    Pages: 67-80
    Download reference. The following formats are available: HTML (with abstract), plain text (with abstract), BibTeX, RIS (EndNote, RefMan, ProCite), ReDIF
    Handle: RePEc:wkh:aheahp:v:6:y:2008:i:1:p:67-80

    Contact details of provider:
    Web page: http://healtheconomics.adisonline.com/

    For corrections or technical questions regarding this item, or to correct its listing, contact: (Dave Dustin).

    Related research

    Keywords: Cost-effectiveness; Disease-prevention; Implantable-cardioverter-defibrillators; Markov-model;

    Find related papers by JEL classification:

    References

    No references listed on IDEAS
    You can help add them by filling out this form.

    Citations

    Lists

    This item is not listed on Wikipedia, on a reading list or among the top items on IDEAS.

    Statistics

    Access and download statistics

    Corrections

    When requesting a correction, please mention this item's handle: RePEc:wkh:aheahp:v:6:y:2008:i:1:p:67-80

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (Dave Dustin).

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If references are entirely missing, you can add them using this form.

    If the full references list an item that is present in RePEc, but the system did not link to it, you can help with this form.

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your profile, as there may be some citations waiting for confirmation.

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.